中国药物经济学2025，Vol.20Issue(2)：111-115,5.DOI:10.12010/j.issn.1673-5846.2025.02.023
淫羊藿苷抗骨质疏松症作用及机制研究进展
Research Progress of Icariin in The Treatment of Osteoporosis
摘要
Abstract
Osteoporosis(OP)is a systemic bone disease that is prone to fractures due to a decrease in bone density and bone quality due to a variety of reasons,destruction of bone microstructure,and increased bone fragility.Traditional Chinese medicine in the treatment of OP has the advantages of high efficacy,multi-target,and economic benefits.As one of the main active ingredients of traditional Chinese medicine Epimedium,icariin(ICA)has the dual activities of promoting bone formation and inhibiting bone resorption,and has become a research hotspot in the treatment of OP with traditional Chinese medicine.By analyzing the research results at home and abroad in recent years,the following review will be made from the research results of ICA on the cell and animal level,as well as the research status of improving drug availability,so as to provide references for the clinical application of ICA in the treatment of OP.关键词
淫羊藿苷/骨质疏松症/破骨细胞/成骨细胞Key words
Icariin/Osteoporosis/Osteoclasts/Osteoblasts分类
医药卫生引用本文复制引用
包卓玛,江露,李玮怡,张宗星,刘道忠,袁林..淫羊藿苷抗骨质疏松症作用及机制研究进展[J].中国药物经济学,2025,20(2):111-115,5.基金项目
恩施土家族苗族自治州科技局指导计划项目(恩施科业[2019]15号) （恩施科业[2019]15号）
